Videos
Advertisement
Ro Patrick and Dr. Jose Prince talk about the responsibility and unique role HCPs play in helping to prevent gun violence.
Faith Lynch, president-elect of ANNA, discussed her upcoming term and challenges faced by nephrology nurses.
Dr. Anne Marie Morse elucidates how DST affects our sleep cycles and why our bodies may feel different while adjusting.
Babak Orandi spoke with us about a study showing that GLP-1 drugs have benefits for kidney transplant recipients with T2D.
Dr. Anne Marie Morse, about the significance and theme of this year’s World Sleep Day.
Dr. John Fruehauf details how novel therapies have improved the landscape of metastatic melanoma care.
Dr. Cytryn shares insights on the implications of recent data from the DESTINY-Gastric04 and MATTERHORN trials.
Dr. Amin Mirhadi details the benefits and disadvantages of using proton therapy in patients with head and neck cancer.
Dr. Anne Marie Morse explains the bidirectional relationship between depression and sleep health, and how it impacts HCPs.
Kirk Huntsman, Chairman & CEO of Vivos Therapeutics, on advancing care in the sleep medicine space.
Eledon Pharmaceuticals CEO David-Alexandre Gros, MD, spoke about the role of CD40L blocker tegoprubart in transplantation.
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
Dr. Albiges shares her thoughts on the FDA approval of subcutaneous nivo in gastric cancer and how it will impact practice.
Dr. Liu unpacks the trial results, the recent approval, and the unique biomarker testing considerations for NRG1 fusions.
Dr. Anne Marie Morse discusses the troubling connection between sleep disorders and dementia.
Thomas Ruggia, CEO of Samsara Vision, talks about a novel implantation device for age-related macular degeneration.
Nephrology Times spoke with Amber Sanchez, MD, about the use of apheresis in nephrology.
Challenges in designing and conducting clinical trials for patients with metastatic pancreatic ductal cancer are discussed.
The efficacy and safety of MEK inhibitors are compared to chemotherapy and other targeted therapies.
The KRAS G12R mutation is analyzed against other alterations in pancreatic adenocarcinoma, and research findings are shared.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.